Response

Journal of the National Cancer Institute

Volumn 104, Issue 16, 2012, Pages 1268-

  Kelly, Catherine M ^a   Pritchard, Kathleen I ^b  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CYTOCHROME P450 2D6; PLACEBO; TAMOXIFEN;

BREAST CANCER; CANCER PATIENT; FEMALE; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; LETTER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84865477814     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs303     Document Type: Letter

References (3)

1. Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ. 2010;340:c693.
2. Pritchard KI. Should observational studies be a thing of the past? J Natl Cancer Inst. 2008;100:451-452.
3. Simon RM, Paik S, Hayes DF. Use of archieved specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101:1446-1452.